Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:ACTU NASDAQ:DERM OTCMKTS:MRMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.63+3.8%$1.53$1.05▼$5.17$170M0.31.35 million shs779,761 shsACTUActuate Therapeutics$8.02-0.6%$7.24$5.47▼$11.99$165.20MN/A103,047 shs115,923 shsDERMJourney Medical$7.57+3.7%$7.14$3.54▼$8.25$170.06M0.8112,276 shs71,427 shsMRMDMariMed$0.10+1.0%$0.09$0.07▼$0.29$37.68M3.02447,868 shs389,204 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+3.82%+6.54%+5.84%+29.37%+36.97%ACTUActuate Therapeutics-0.62%+10.47%+21.33%-22.51%+801,999,900.00%DERMJourney Medical+3.70%+8.30%+6.02%+10.03%+53.86%MRMDMariMed+1.04%0.00%-2.99%+2.63%-42.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRSAclaris Therapeutics2.1443 of 5 stars3.61.00.00.02.51.70.6ACTUActuate Therapeutics1.8512 of 5 stars3.50.00.00.00.63.30.0DERMJourney Medical1.8808 of 5 stars3.51.00.00.02.50.80.6MRMDMariMed0.7565 of 5 stars0.03.00.00.02.40.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.11Buy$8.71434.62% UpsideACTUActuate Therapeutics 3.00Buy$20.50155.61% UpsideDERMJourney Medical 3.00Buy$9.5025.50% UpsideMRMDMariMed 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest MRMD, ACRS, ACTU, and DERM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025ACRSAclaris TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$6.006/25/2025ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/23/2025ACRSAclaris TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$8.006/3/2025ACTUActuate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy$20.005/28/2025ACRSAclaris TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$8.005/15/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/14/2025ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $16.005/9/2025ACRSAclaris TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $9.00(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$18.72M9.43N/AN/A$1.44 per share1.13ACTUActuate TherapeuticsN/AN/AN/AN/A$0.01 per shareN/ADERMJourney Medical$56.13M3.14N/AN/A$0.91 per share8.32MRMDMariMed$157.96M0.24$0.02 per share4.47$0.16 per share0.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$132.07M-$1.39N/AN/AN/A-802.03%-33.33%-23.84%N/AACTUActuate Therapeutics-$27.28MN/A0.00∞N/AN/AN/A-339.73%N/ADERMJourney Medical-$14.67M-$0.39N/AN/AN/A-14.76%-52.03%-11.28%8/12/2025 (Estimated)MRMDMariMed-$12.16M-$0.03N/A∞N/A-10.14%-10.35%-3.08%N/ALatest MRMD, ACRS, ACTU, and DERM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025DERMJourney Medical-$0.06N/AN/AN/A$14.93 millionN/A8/7/2025Q2 2025ACRSAclaris Therapeutics-$0.14-$0.13+$0.01-$0.13$1.34 million$1.78 million5/15/2025Q1 2025ACTUActuate Therapeutics-$0.26-$0.32-$0.06-$0.32N/AN/A5/14/2025Q1 2025DERMJourney Medical-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AACTUActuate TherapeuticsN/AN/AN/AN/AN/ADERMJourney MedicalN/AN/AN/AN/AN/AMRMDMariMedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A5.065.06ACTUActuate TherapeuticsN/A0.460.46DERMJourney Medical1.071.341.03MRMDMariMed1.211.050.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%ACTUActuate TherapeuticsN/ADERMJourney Medical7.25%MRMDMariMed0.18%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics6.40%ACTUActuate Therapeutics69.34%DERMJourney Medical15.03%MRMDMariMed18.99%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100108.28 million101.35 millionOptionableACTUActuate Therapeutics1020.47 million6.28 millionN/ADERMJourney Medical9023.30 million19.80 millionN/AMRMDMariMed260390.43 million316.29 millionNot OptionableMRMD, ACRS, ACTU, and DERM HeadlinesRecent News About These CompaniesMariMed Inc. (MRMD) Q2 2025 Earnings Call TranscriptAugust 7 at 11:01 PM | seekingalpha.comMariMed (MRMD) Q2 EPS Jumps to PositiveAugust 6 at 12:11 AM | fool.comMariMed Inc. (MRMD) Reports Break-Even Earnings for Q2August 6 at 8:06 PM | zacks.comMariMed Reports Second Quarter 2025 EarningsAugust 6 at 5:00 PM | globenewswire.comMariMed (MRMD) Projected to Post Quarterly Earnings on WednesdayAugust 5, 2025 | americanbankingnews.comMariMed’s Products to Enter Pennsylvania Market Through a Management Services and Licensing Agreement with TILT HoldingsJuly 31, 2025 | finance.yahoo.comMariMed's Products to Enter Pennsylvania Market Through a Management Services and Licensing Agreement with TILT HoldingsJuly 31, 2025 | globenewswire.comCORRECTION -- MariMed Expands Access to Top-Selling Betty’s Eddies Brand in MaineJuly 14, 2025 | uk.finance.yahoo.comMariMed Expands Access to Top-Selling Betty’s Eddies Brand in MaineJuly 14, 2025 | finance.yahoo.comCORRECTION -- MariMed Expands Access to Top-Selling Betty's Eddies Brand in MaineJuly 14, 2025 | globenewswire.comMariMed Expands Access to Top-Selling Betty's Eddies Brand in MaineJuly 14, 2025 | globenewswire.comMariMed Expands Access to Top-Selling Betty's Eddies Brand in MaineJuly 14, 2025 | globenewswire.comMariMed Announces Second Quarter 2025 Earnings DateJuly 8, 2025 | globenewswire.comMariMed Statement Regarding the Commencement of Adult-Use Cannabis Sales in Delaware on August 1stJuly 1, 2025 | globenewswire.comMariMed Inc. (MRMD) Latest Stock News & Headlines - Yahoo FinanceJune 24, 2025 | finance.yahoo.comMariMed’s Premium Nature’s Heritage Brand Enters Functional Mushroom Market Launching Plant-Based MycroDoseMay 29, 2025 | uk.finance.yahoo.comMariMed's Premium Nature's Heritage Brand Enters Functional Mushroom Market Launching Plant-Based MycroDoseMay 29, 2025 | globenewswire.comEarnings call transcript: Marimed’s Q1 2025 revenue flat, stock edges upMay 9, 2025 | investing.comMariMed Inc. (PNK:MRMD) Q1 2025 Earnings Call TranscriptMay 9, 2025 | insidermonkey.comMariMed Inc (MRMD) Q1 2025 Earnings Call Highlights: Strategic Expansion Amidst Market ChallengesMay 9, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesForget the Hype—TSMC Is the AI Stock That Actually DeliversBy Gabriel Osorio-Mazilli | July 22, 2025View Forget the Hype—TSMC Is the AI Stock That Actually DeliversTaiwan Semiconductor Could Boom on This AI Action PlanBy Gabriel Osorio-Mazilli | July 28, 2025View Taiwan Semiconductor Could Boom on This AI Action Plan3 ETFs to Buy as the One Big Beautiful Bill Rolls OutBy Nathan Reiff | July 21, 2025View 3 ETFs to Buy as the One Big Beautiful Bill Rolls OutAmazon Enters Correction Zone: Time to Panic or Be Brave?By Sam Quirke | August 5, 2025View Amazon Enters Correction Zone: Time to Panic or Be Brave?Vertical Aerospace's New Deal and Earnings De-Risk ProductionBy Jeffrey Neal Johnson | August 5, 2025View Vertical Aerospace's New Deal and Earnings De-Risk ProductionMRMD, ACRS, ACTU, and DERM Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$1.63 +0.06 (+3.82%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.60 -0.03 (-2.09%) As of 08/8/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Actuate Therapeutics NASDAQ:ACTU$8.02 -0.05 (-0.62%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$8.04 +0.02 (+0.25%) As of 08/8/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Journey Medical NASDAQ:DERM$7.57 +0.27 (+3.70%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$7.54 -0.03 (-0.40%) As of 08/8/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.MariMed OTCMKTS:MRMD$0.10 +0.00 (+1.04%) As of 08/8/2025 03:51 PM EasternMariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
